cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Springworks Therapeutics Inc
1 own
6 watching
Current Price
$23.79
$-0.4
(-1.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,698.14M
52-Week High
52-Week High
34.16000
52-Week Low
52-Week Low
21.04000
Average Volume
Average Volume
0.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,698.14M
icon52-Week High34.16000
icon52-Week Low21.04000
iconAverage Volume0.3M
iconDividend Yield--
iconP/E Ratio--
What does the Springworks Therapeutics Inc do?
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Read More
How much money does Springworks Therapeutics Inc make?
News & Events about Springworks Therapeutics Inc.
Globe Newswire
7 months ago
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) on behalf of the companys long-term investors. The investigation seeks to determine whether SpringWorks has issued false and misleading statements and/or ...
Globe Newswire
9 months ago
STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that the Company has completed the submission ...
PR Newswire
11 months ago
Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma PR Newswire CONCORD, Mass...
Frequently Asked Questions
Frequently Asked Questions
What is Springworks Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Springworks Therapeutics Inc shares?
plus_minus_icon
How can I buy Springworks Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Springworks Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Springworks Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Springworks Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Springworks Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Springworks Therapeutics Inc?
plus_minus_icon
What percentage is Springworks Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Springworks Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$23.79
$-0.4
(-1.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$28.67
$-0.94 (-3.17 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$19.19
$0.53 (2.84 %)
Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
$20.57
$0.15 (0.73 %)
CureVac
CureVac
$7.36
$-0.06 (-0.81 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$28.67
$-0.94 (-3.17 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$19.19
$0.53 (2.84 %)
Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
$20.57
$0.15 (0.73 %)
CureVac
CureVac
$7.36
$-0.06 (-0.81 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00